Evidence map›Paper›PMID 39145449›Full record

ReviewThe Journal of clinical investigation2024

Human genetics and epigenetics of alcohol use disorder.

Hang Zhou, Joel Gelernter

Abstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Validation ofInternational journal of molecular sciences · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hang ZhouDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.
Joel GelernterDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.

Funding

Translational Technologies CoreP50AA012870 · NIAAA · YALE UNIVERSITY · PI John H. Krystal · 2001 to 2026
$43.7M
Yale-SCORE Resource Support CoreU54AA027989 · NIAAA · YALE UNIVERSITY · PI ISMENE L. PETRAKIS · 2020 to 2026
$13.0M
Genetic & Social Determinants of Health: Center for Admixture Science and TechnologyRM1HG011558 · NHGRI · YALE UNIVERSITY · PI FRAZER, KELLY A, GYMREK, MELISSA · 2021 to 2025
$11.2M
Methamphetamine and Other Substance Use Disorder Genetics in ThailandR01DA037974 · NIDA · YALE UNIVERSITY · PI JOEL GELERNTER, Marc N Potenza · 2015 to 2026
$6.7M
Genetics of Alcohol Dependence in African Americans: RecruitmentR01AA026364 · NIAAA · YALE UNIVERSITY · PI GELERNTER, JOEL · 2018 to 2022
$2.0M
Genetic Causality of Alcohol Intake and Alcohol Use Disorder on Cancer RiskR21CA252916 · NCI · YALE UNIVERSITY · PI ZHOU, HANG · 2021 to 2022
$334k
Genomics of PTSD and Related TraitsI01CX001849 · VA · VA CONNECTICUT HEALTHCARE SYSTEM · PI GELERNTER, JOEL, STEIN, MURRAY B. · 2019 to 2022
–
CSRD VA I01 CX001849NCI NIH HHS R21 CA252916NHGRI NIH HHS RM1 HG011558NIAAA NIH HHS P50 AA012870NIAAA NIH HHS R01 AA026364NIAAA NIH HHS U54 AA027989NIDA NIH HHS R01 DA037974
6 · The paper itself

Abstract

Alcohol use disorder (AUD) is a prominent contributor to global morbidity and mortality. Its complex etiology involves genetics, epigenetics, and environmental factors. We review progress in understanding the genetics and epigenetics of AUD, summarizing the key findings. Advancements in technology over the decades have elevated research from early candidate gene studies to present-day genome-wide scans, unveiling numerous genetic and epigenetic risk factors for AUD. The latest GWAS on more than one million participants identified more than 100 genetic variants, and the largest epigenome-wide association studies (EWAS) in blood and brain samples have revealed tissue-specific epigenetic changes. Downstream analyses revealed enriched pathways, genetic correlations with other traits, transcriptome-wide association in brain tissues, and drug-gene interactions for AUD. We also discuss limitations and future directions, including increasing the power of GWAS and EWAS studies as well as expanding the diversity of populations included in these analyses. Larger samples, novel technologies, and analytic approaches are essential; these include whole-genome sequencing, multiomics, single-cell sequencing, spatial transcriptomics, deep-learning prediction of variant function, and integrated methods for disease risk prediction.

Indexed as

AlcoholismEpigenesis, GeneticGenome-Wide Association StudyGenetic Predisposition to DiseaseHumans

Identifiers

PMID39145449
PMCPMC11324314

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.